<code id='43B437DC4C'></code><style id='43B437DC4C'></style>
    • <acronym id='43B437DC4C'></acronym>
      <center id='43B437DC4C'><center id='43B437DC4C'><tfoot id='43B437DC4C'></tfoot></center><abbr id='43B437DC4C'><dir id='43B437DC4C'><tfoot id='43B437DC4C'></tfoot><noframes id='43B437DC4C'>

    • <optgroup id='43B437DC4C'><strike id='43B437DC4C'><sup id='43B437DC4C'></sup></strike><code id='43B437DC4C'></code></optgroup>
        1. <b id='43B437DC4C'><label id='43B437DC4C'><select id='43B437DC4C'><dt id='43B437DC4C'><span id='43B437DC4C'></span></dt></select></label></b><u id='43B437DC4C'></u>
          <i id='43B437DC4C'><strike id='43B437DC4C'><tt id='43B437DC4C'><pre id='43B437DC4C'></pre></tt></strike></i>

          focus

          focus

          author:leisure time    Page View:79
          Adobe

          Venture firms backing health tech startups are telegraphing cautious optimism for 2024, advising startups to expect smaller and fewer checks as well as possible market consolidation but not to abandon hope just yet as investments stabilize following a sharp drop-off.

          As customers — often health systems, payers, or employers — and backers plot how they’ll invest shrinking budgets, they’re increasingly savvy about metrics, investors told STAT. They’re also less interested in rapid growth, and more keen on startups that can demonstrate savings and efficiency.

          advertisement

          That’s a sharp contrast from the unrestrained health tech investments that peaked in 2021, fueled by a pandemic-era frenzy for virtual appointments, mental health care and app-based therapies.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more
          Bernie Sanders gets little from pharma CEOs on drug prices
          Bernie Sanders gets little from pharma CEOs on drug prices

          Sen.BernieSanders(I-Vt.)raiseshishandataThursdayhearingonCapitolHillinWashingtontoexaminethecostofpr

          read more
          In Memoriam: Notable people who died in 2023
          In Memoriam: Notable people who died in 2023

          1:29AlanArkinattendsthe26thAnnualScreenActorsGuildAwardsatTheShrineAuditoriumonJan.19,2020inLosAngel

          read more

          Readout Newsletter: Amylyx, Aurinia, and IQVIA

          AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo